Alpha-glycerophosphocholine (Alpha-GPC)

COMMON NAME

Alpha-GPC | Glycerophosphocholine | Choline alphoscerate | L-alpha-glycerophosphocholine

TOP BENEFITS OF ALPHA-GPC

Supports cognitive function*

Supports exercise performance* 

WHAT IS ALPHA-GPC?

Alpha-glycerophosphocholine (alpha-GPC) is a choline-containing phospholipid that can be used to augment the body and brain choline pool. In this role it serves as a precursor for both acetylcholine and phosphatidylcholine biosynthesis. Alpha-GPC and citicoline (i.e., CDP-choline) are considered the nootropic forms of choline, with both forms able to increase brain choline levels, act as building blocks for acetylcholine, and support choline-dependent neurotransmission [1–4]. However, of the two, alpha-GPC contains a higher proportion of choline, so a lower dose of alpha-GPC gives greater choline support than a similar dose of citicoline [5–7]. This means that by weight alpha-GPC is the more efficient choline precursor. Following an oral dose, alpha-GPC metabolizes into choline and the phospholipid glycerophosphate. The choline can be used for acetylcholine synthesis and neurotransmission [3,8–14]. Acetylcholine is central to brain neurotransmission; it’s also used in both the fight or flight and rest and relax parts of the autonomic nervous system; and it is a signaling molecule for activating muscles. Because alpha-GPC is a precursor in the biosynthesis of acetylcholine, it plays a supportive role in a variety of cognitive functions, including attention, concentration, mental focus, and memory formation and recall [15]. Alpha-GPC also supports aspects of muscle performance, and is involved in maintaining organs and tissues. And, because alpha-GPC can be readily metabolized into phosphatidylcholine, it can be used to support the structure and function of cell membranes. Alpha-GPC is found in low amounts in a variety of foods [16] and in breast milk [17,18].* 

NEUROHACKER’S ALPHA-GPC SOURCING

Alpha-glycerophosphocholine (Alpha-GPC) is a source of choline; it is able to influence both systemic and brain concentrations of choline.

Alpha-GPC is derived from soy.

Neurohacker uses an Alpha-GPC that is sourced to be non-GMO, gluten-free, and vegan.

ALPHA-GPC FORMULATING PRINCIPLES AND RATIONALE

Alpha-glycerophosphocholine (Alpha-GPC) is by weight one of the best sources of choline. While alpha-GPC is often treated as if it’s dose-dependent (i.e., a higher dose is better) and doses of 1200 mg/day have been used in some clinical studies, Neurohacker believes the evidence suggests a threshold response (see Neurohacker Dosing Principles) when alpha-GPC is given to healthy people. This means that more might not be better under all circumstances. As an example, in a study of healthy college-aged men, while the higher dose (500 mg/day) of alpha-GPC did a better job increasing free choline levels, the lower dose (250 mg/day) produced a better peak muscle force response [19]. In general, Neurohacker’s experience with alpha-GPC (as well as citicoline) indicates that when used as part of comprehensive nootropic formulations, a more modest serving is often sufficient. Alpha-GPC is a useful choline source in liquids because of its taste and solubility. In general, the best time to take alpha-GPC is early in the day.*

ALPHA-GPC KEY MECHANISMS

Augments choline pool*

Alpha-GPC is part of the CDP-choline (or Kennedy) pathway, which has a central role in choline homeostasis* [13,14]

Supports plasma choline levels* [20]

Precursor for phosphatidylcholine synthesis* [3]

Precursor for acetylcholine synthesis* [2,3]

Supports brain function*

Supports cognitive function* [2,3,7,15,21–23]

Supports acetylcholine signaling* [2,3,24–26]

Supports dopamine signaling* [1,27]

Supports serotonin signaling* [27]

Supports GABA signaling* [28]

Supports phospholipid synthesis* [9,29]

Supports growth hormone secretion from the pituitary gland* [10,20,30]

Counters some age-related brain microstructural changes* [31–34]

Supports neuroprotective functions* [2,3]

Promotes exercise performance*

Supports isometric force production* [35]

Supports maximum power and velocity in jump movements* [19]

REFERENCES 

[1]M. Trabucchi, S. Govoni, F. Battaini, Farmaco Sci. 41 (1986) 325–334.

[2]C.M. Lopez, S. Govoni, F. Battaini, S. Bergamaschi, A. Longoni, C. Giaroni, M. Trabucchi, Pharmacol. Biochem. Behav. 39 (1991) 835–840.

[3]S. Sigala, A. Imperato, P. Rizzonelli, P. Casolini, C. Missale, P. Spano, Eur. J. Pharmacol. 211 (1992) 351–358.

[4]N. Canal, Others, Le Basi Raz Ter 23 (1993) 102.

[5]R. Di Perri, G. Coppola, L.A. Ambrosio, A. Grasso, F.M. Puca, M. Rizzo, J. Int. Med. Res. 19 (1991) 330–341.

[6]G. Gatti, N. Barzaghi, G. Acuto, G. Abbiati, T. Fossati, E. Perucca, Int. J. Clin. Pharmacol. Ther. Toxicol. 30 (1992) 331–335.

[7]L. Parnetti, F. Mignini, D. Tomassoni, E. Traini, F. Amenta, J. Neurol. Sci. 257 (2007) 264–269.

[8]I.H. Ulus, R.J. Wurtman, C. Mauron, J.K. Blusztajn, Brain Res. 484 (1989) 217–227.

[9]G. Abbiati, T. Fossati, G. Lachmann, M. Bergamaschi, C. Castiglioni, Eur. J. Drug Metab. Pharmacokinet. 18 (1993) 173–180.

[10]G.P. Ceda, G.P. Marzani, V. Tontodonati, E. Piovani, A. Banchini, M.T. Baffoni, G. Valenti, A.R. Hoffman, in: Growth Hormone II, Springer New York, 1994, pp. 328–337.

[11]J.P. Fernández-Murray, C.R. McMaster, J. Biol. Chem. 280 (2005) 38290–38296.

[12]F. Amenta, S.K. Tayebati, D. Vitali, M.A. Di Tullio, Mech. Ageing Dev. 127 (2006) 173–179.

[13]Z. Li, D.E. Vance, J. Lipid Res. 49 (2008) 1187–1194.

[14]F. Gibellini, T.K. Smith, IUBMB Life 62 (2010) 414–428.

[15]N. Canal, M. Franceschi, M. Alberoni, C. Castiglioni, P. De Moliner, A. Longoni, Int. J. Clin. Pharmacol. Ther. Toxicol. 29 (1991) 103–107.

[16]S.H. Zeisel, M.-H. Mar, J.C. Howe, J.M. Holden, The Journal of Nutrition 133 (2003) 1302–1307.

[17]M.Q. Holmes-McNary, W.L. Cheng, M.H. Mar, S. Fussell, S.H. Zeisel, Am. J. Clin. Nutr. 64 (1996) 572–576.

[18]Y.O. Ilcol, R. Ozbek, E. Hamurtekin, I.H. Ulus, J. Nutr. Biochem. 16 (2005) 489–499.

[19]L. Marcus, J. Soileau, L.W. Judge, D. Bellar, J. Int. Soc. Sports Nutr. 14 (2017) 39.

[20]T. Kawamura, T. Okubo, K. Sato, S. Fujita, K. Goto, T. Hamaoka, M. Iemitsu, Nutrition 28 (2012) 1122–1126.

[21]F. Amenta, A. Carotenuto, A.M. Fasanaro, R. Rea, E. Traini, J. Neurol. Sci. 322 (2012) 96–101.

[22]L. Parnetti, F. Amenta, V. Gallai, Mech. Ageing Dev. 122 (2001) 2041–2055.

[23]G. Schettini, C. Ventra, T. Florio, M. Grimaldi, O. Meucci, A. Scorziello, A. Postiglione, A. Marino, Pharmacol. Biochem. Behav. 43 (1992) 139–151.

[24]S.K. Tayebati, D. Tomassoni, A. Di Stefano, P. Sozio, L.S. Cerasa, F. Amenta, J. Neurol. Sci. 302 (2011) 49–57.

[25]D. Tomassoni, A. Catalani, C. Cinque, M.A. Di Tullio, S.K. Tayebati, A. Cadoni, I.E. Nwankwo, E. Traini, F. Amenta, Curr. Alzheimer Res. 9 (2012) 120–127.

[26]F. Amenta, F. Franch, A. Ricci, J.A. Vega, Ann. N. Y. Acad. Sci. 695 (1993) 311–313.

[27]S.K. Tayebati, D. Tomassoni, I.E. Nwankwo, A. Di Stefano, P. Sozio, L.S. Cerasa, F. Amenta, CNS & Neurological Disorders - Drug Targets 12 (2013) 94–103.

[28]L. Ferraro, S. Tanganelli, L. Marani, C. Bianchi, L. Beani, A. Siniscalchi, Neurochem. Res. 21 (1996) 547–552.

[29]G. Aleppo, F. Nicoletti, M.A. Sortino, G. Casabona, U. Scapagnini, P.L. Canonico, Pharmacol. Toxicol. 74 (1994) 95–100.

[30]G.P. Ceda, G. Ceresini, L. Denti, G. Marzani, E. Piovani, A. Banchini, E. Tarditi, G. Valenti, Horm. Metab. Res. 24 (1992) 119–121.

[31]F. Amenta, M. Del Valle, J.A. Vega, D. Zaccheo, Mech. Ageing Dev. 61 (1991) 173–186.

[32]A. Ricci, E. Bronzetti, J.A. Vega, F. Amenta, Mech. Ageing Dev. 66 (1992) 81–91.

[33]F. Amenta, F. Ferrante, J.A. Vega, D. Zaccheo, Prog. Neuropsychopharmacol. Biol. Psychiatry 18 (1994) 915–924.

[34]G. Muccioli, G.M. Raso, C. Ghé, R. Di Carlo, Prog. Neuropsychopharmacol. Biol. Psychiatry 20 (1996) 323–339.